[go: up one dir, main page]

FR2918388B1 - Enzyme cible dans le traitement de l'acne. - Google Patents

Enzyme cible dans le traitement de l'acne.

Info

Publication number
FR2918388B1
FR2918388B1 FR0756309A FR0756309A FR2918388B1 FR 2918388 B1 FR2918388 B1 FR 2918388B1 FR 0756309 A FR0756309 A FR 0756309A FR 0756309 A FR0756309 A FR 0756309A FR 2918388 B1 FR2918388 B1 FR 2918388B1
Authority
FR
France
Prior art keywords
acne
treatment
target enzyme
enzyme
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0756309A
Other languages
English (en)
Other versions
FR2918388A1 (fr
Inventor
Laurent Lamy
Michel Rivier
Gerard Feraille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0756309A priority Critical patent/FR2918388B1/fr
Priority to EP08826450A priority patent/EP2167677A2/fr
Priority to PCT/FR2008/051269 priority patent/WO2009010687A2/fr
Priority to CA2693153A priority patent/CA2693153A1/fr
Publication of FR2918388A1 publication Critical patent/FR2918388A1/fr
Application granted granted Critical
Publication of FR2918388B1 publication Critical patent/FR2918388B1/fr
Priority to US12/652,283 priority patent/US20100168231A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0756309A 2007-07-06 2007-07-06 Enzyme cible dans le traitement de l'acne. Expired - Fee Related FR2918388B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0756309A FR2918388B1 (fr) 2007-07-06 2007-07-06 Enzyme cible dans le traitement de l'acne.
EP08826450A EP2167677A2 (fr) 2007-07-06 2008-07-07 Enzyme cible dans le traitement de l'acne
PCT/FR2008/051269 WO2009010687A2 (fr) 2007-07-06 2008-07-07 Enzyme cible dans le traitement de l'acne
CA2693153A CA2693153A1 (fr) 2007-07-06 2008-07-07 Enzyme cible dans le traitement de l'acne
US12/652,283 US20100168231A1 (en) 2007-07-06 2010-01-05 Target enzyme for the treatment of acne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0756309A FR2918388B1 (fr) 2007-07-06 2007-07-06 Enzyme cible dans le traitement de l'acne.

Publications (2)

Publication Number Publication Date
FR2918388A1 FR2918388A1 (fr) 2009-01-09
FR2918388B1 true FR2918388B1 (fr) 2009-10-23

Family

ID=39027085

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0756309A Expired - Fee Related FR2918388B1 (fr) 2007-07-06 2007-07-06 Enzyme cible dans le traitement de l'acne.

Country Status (5)

Country Link
US (1) US20100168231A1 (fr)
EP (1) EP2167677A2 (fr)
CA (1) CA2693153A1 (fr)
FR (1) FR2918388B1 (fr)
WO (1) WO2009010687A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7358800A (en) * 1999-09-10 2001-04-10 Applied Genetics Incorporated Dermatics Compositions and methods for modification of skin lipid content
GB0020351D0 (en) * 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
FR2918388A1 (fr) 2009-01-09
US20100168231A1 (en) 2010-07-01
WO2009010687A2 (fr) 2009-01-22
WO2009010687A3 (fr) 2009-05-22
CA2693153A1 (fr) 2009-01-22
EP2167677A2 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
BRPI0819582A2 (pt) "sistema de tratamento de líquido"
EP2062167A4 (fr) Navigation efficace dans des résultats de recherche
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
EP2185202A4 (fr) Utilisation de l'interleukine-22 dans le traitement de la stéatose hépatique
BRPI0814894A2 (pt) Diferenciação de células-tronco embrionárias de ser humano.
EP1979472A4 (fr) Determination metabolique dans une technologie de procreation medicalement assistee
BRPI0814307A2 (pt) Sistema de tratamento presbiópico
EP2020970A4 (fr) Traitement de l'oeil
BRPI0810227A2 (pt) Tratamento de água com baixo potencial de incrustação
EP2201513A4 (fr) Traitement différencié de résultats de recherche parrainés sur la base du contexte de recherche
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
EP2376091A4 (fr) Nouvelles cibles pour le traitement de l'hypercholestérolémie
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
IL216369B (en) Alpha-difluoromethylornithine for carcinoma diagnosis and treatment of patients with odc1 genotype
EP2101789A4 (fr) Inhibiteur de télomérase combiné à la gemcitabine dans le traitement du cancer
EP2205243A4 (fr) Stabilisateurs de cellules mast dans le traitement de l'obésité
EP2211861A4 (fr) Clioquinol dans le traitement de malignités hématologiques
EP2488507A4 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
FR2934267B1 (fr) Derives aminophosphiniques utiles dans le traitement de la douleur
FR2934052B1 (fr) Dosage de l'activite du facteur tissulaire circulant
EP2484670A4 (fr) Substitués 1,2,4-tiadiazoles-5-imino utiles dans le traitement de maladies neurodégénératives
BRPI1010256A2 (pt) "aplicações terapêuticas no domínio cardiovascular de derivados de quinazolina diona."
FR2927329B1 (fr) Procede ameliore de preparation d'anhydride (meth)acrylique.
FR2899476B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20120330